• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

5.950 -0.040 (-0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Taysha Gene Therapies Q2 Earnings Call Highlights ↗
August 11, 2026
Taysha Gene Therapies (NASDAQ:TSHA) said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential... 
Via MarketBeat
Topics Earnings
News headline image
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
August 04, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
Taysha Gene Therapies (NASDAQ:TSHA) Reports Q1 2026 Miss, Reaffirms FDA Alignment on TSHA-102 Approval Path ↗
May 06, 2026
Via Chartmill
Taysha Gene Therapies Inc (NASDAQ:TSHA) Reports Q4 2025 Revenue Beat and Key Rett Syndrome Program Updates ↗
March 19, 2026
Via Chartmill
News headline image
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
August 03, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run ↗
July 12, 2026
Nagendran Sukumar executed the sale under a pre-established Rule 10b5-1 trading plan, retaining 936,410 shares worth $5.94 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
June 25, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 4, 2025 ↗
November 04, 2025
 
Via Benzinga
News headline image
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 24, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 24, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
June 22, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha (TSHA) Q1 2026 Earnings Transcript ↗
May 07, 2026
Taysha (TSHA) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 06, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
April 29, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
April 27, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug... 
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
March 22, 2026
Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline. 
Via The Motley Fool
News headline image
Taysha (TSHA) Q4 2025 Earnings Call Transcript ↗
March 19, 2026
Taysha (TSHA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
March 19, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
March 12, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Inc (NASDAQ:TSHA) Stock Slumps on Q3 Revenue Miss Despite Key Regulatory Win for TSHA-102 ↗
November 04, 2025
Taysha Gene Therapies stock fell after Q3 results, with a revenue miss overshadowing positive FDA Breakthrough Therapy designation for its Rett syndrome drug. 
Via Chartmill
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
October 20, 2025
 
Via Benzinga
News headline image
Why Is Taysha Gene Therapies Stock Falling Friday? ↗
October 17, 2025
Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial. 
Via Benzinga
News headline image
Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals ↗
October 03, 2025
Taysha shares jumped after analysts at Baird, H.C. Wainwright, and Needham turned bullish, citing FDA alignment and an expedited approval path for its Rett syndrome therapy. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap